Epidemiology, Clinical Characteristics and Outcomes of Extensively Drug-Resistant Acinetobacter baumannii Infections among Solid Organ Transplant Recipients

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Shields, Ryan K ^a,b   Clancy, Cornelius J ^a,c   Gillis, Louise M ^b,d   Kwak, Eun J ^a,b   Silveira, Fernanda P ^a   Massih, Rima C Abdel ^a,b   Eschenauer, Gregory A ^b   Potoski, Brian A ^a,b,d   Nguyen, M Hong ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CARBAPENEM; CEFEPIME; COLISTIN; DORIPENEM; MEROPENEM; RIFAMPICIN; SULTAMICILLIN; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM ISOLATE; CLINICAL FEATURE; DRUG RESPONSE; EXTENSIVELY DRUG RESISTANT ACINETOBACTER BAUMANNII; EXTENSIVELY DRUG RESISTANT ACINETOBACTER BAUMANNII INFECTION; FEMALE; GRAFT RECIPIENT; HEART TRANSPLANTATION; HIGH RISK POPULATION; HUMAN; INTESTINE TRANSPLANTATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PANCREAS TRANSPLANTATION; RECURRENCE RISK; RECURRENT INFECTION; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; THORAX SURGERY; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRANSPLANTS; YOUNG ADULT;

ACINETOBACTER BAUMANNII;

EID: 84871440614     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052349     Document Type: Article

References (56)

1. Saner FH, Olde Damink SW, Pavlakovic G, van den Broek MA, Rath PM, et al. (2008) Pulmonary and blood stream infections in adult living donor and cadaveric liver transplant patients. Transplantation 85: 1564-1568.
2. Benden C, Aurora P, Edwards LB, Kucheryavaya AY, Christie JD, et al. (2011) The Registry of the International Society for Heart and Lung Transplantation: Fourteenth Pediatric Lung and Heart-Lung Transplantation Report-2011. J Heart Lung Transplant 30: 1123-1132.
3. Boucher HW, Talbot GH, Bradley JS, Edwards JE Jr, Gilbert D, et al. (2009) Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48: 1-12.
4. Shields RK, Kwak EJ, Potoski BA, Doi Y, Adams-Haduch JM, et al. (2011) High mortality rates among solid organ transplant recipients infected with extensively drug-resistant Acinetobacter baumannii: using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen. Diagn Microbiol Infect Dis 70: 246-252.
5. Reddy P, Zembower TR, Ison MG, Baker TA, Stosor V, (2010) Carbapenem-resistant Acinetobacter baumannii infections after organ transplantation. Transpl Infect Dis 12: 87-93.
6. Falagas ME, Karveli EA, Siempos II, Vardakas KZ, (2008) Acinetobacter infections: a growing threat for critically ill patients. Epidemiol Infect 136: 1009-1019.
7. Giamarellou H, Antoniadou AK, Kanellakopoulou K, (2008) Acinetobacter baumannii: a universal threat to public health? Int J Antimicrob Agents 32: 106-119.
8. Nunley DR, Bauldoff GS, Mangino JE, Pope-Harman AL, (2010) Mortality associated with Acinetobacter baumannii infections experienced by lung transplant recipients. Lung 188: 381-385.
9. Kim YJ, Yoon JH, Kim SI, Hong KW, Kim JI, et al. (2011) High mortality associated with Acinetobacter species infection in liver transplant patients. Transplant Proc 43: 2397-2399.
10. Mak JK, Kim M, Pham J, Tapsall J, White PA, (2009) Antibiotic resistance determinants in nosocomial strains of multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 63: 47-54.
11. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, et al. (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18: 268-281.
12. Husain S, Mooney ML, Danziger-Isakov L, Mattner F, Singh N, et al. (2011) A 2010 working formulation for the standardization of definitions of infections in cardiothoracic transplant recipients. J Heart Lung Transplant 30: 361-374.
13. Horan TC, Andrus M, Dudeck MA, (2008) CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 36: 309-332.
14. Clinical and Laboratory Standards Institute (2009) Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard- Eighth Edition: Approved Standard M07-A8. Wayne, PA CLSI.
15. Peleg AY, Potoski BA, Rea R, Adams J, Sethi J, et al. (2007) Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 59: 128-131.
16. Esterly JS, Griffith M, Qi C, Malczynski M, Postelnick MJ, et al. (2011) Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections. Antimicrob Agents Chemother 55: 4844-4849.
17. Kalin G, Alp E, Coskun R, Demiraslan H, Gundogan K, et al. (2012) Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia: do we really need this treatment? J Infect Chemother.
18. Hogg GM, Barr JG, Webb CH, (1998) In-vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother 41: 494-495.
19. Tascini C, Menichetti F, Bozza S, DelFavero A, Bistoni F, (1998) Evaluation of the activities of two-drug combinations of rifampicin, polymyxin B and ampicillin/sulbactam against Acinetobacter baumannii. J Antimicrob Chemother 42: 270-271.
20. Giamarellos-Bourboulis EJ, Xirouchaki E, Giamarellou H, (2001) Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 40: 117-120.
21. Yoon J, Urban C, Terzian C, Mariano N, Rahal JJ, (2004) In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin againsts multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 48: 753-757.
22. Choi JY, Park YS, Cho CH, Park YS, Shin SY, et al. (2004) Synergic in-vitro activity of imipenem and sulbactam against Acinetobacter baumannii. Clin Microbiol Infect 10: 1089-1104.
23. Haddad FA, VanHorn K, Carbonaro C, Aguero-Rosenfeld M, Wormser GP, (2005) Evaluation of antibiotic combinations against multidrug-resistant Acinetobacter baumannii using the E-test. Eur J Clin Microbiol Infect Dis 24: 577-579.
24. Kiffer CRV, Sampaio JLM, Sinto S, Oplustil CP, Koga PCM, et al. (2005) In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii. Diagn Microbiol Infect Dis 52: 317-322.
25. Tripodi MF, Durante-Mangoni E, Fortunato R, Utili R, Zarrilli R, (2007) Comparative activities of colistin, rifampin, imipenem, and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases. Int J Antimicrob Agents 30: 537-540.
26. Song JY, Kee SY, Hwang IS, Seo YB, Jeong HW, et al. (2007) In vitro acitivities of carbapenem/sulbactam combination, colistin, colistin/rifampin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 60: 317-322.
27. Sands M, McCarter Y, Sanchez W, (2007) Synergy testing of multidrug-resistant Acinetobacter baumannii against tigecycline and polymyxin using an E-test methodology. Eur J Clin Microbiol Infect Dis 26: 521-522.
28. Sheetz MH, Qi C, Warren JR, Postelnick MJ, Zembower T, et al. (2007) In vitro activities of various antimicrobials alone and in combination with tigecycline againsts carbapenem-intermediate or-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 51: 1621-1626.
29. Arroyo LA, Mateos I, Gonzalez V, Aznar J, (2009) In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group. Antimicrob Agents Chemother 53: 1295-1296.
30. Principe L, D'Arezzo S, Capone A, Petrosillo N, Visca P, (2009) In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii. Ann Clin Microbiol Antimicrob 8: 18-28.
31. Sopirala MM, Mangino JE, Gebreyes WA, Biller B, Bannerman T, et al. (2010) Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 54: 4678-4683.
32. Kempf M, Djouhri-Bouktab L, Brunel JM, Raoult D, Rolain JM, (2012) Synergistic activity of sulbactam combined with colistin against colistin-resistant Acinetobacter baumannii. Int J Antimicrob Agents 39: 180-181.
33. Bassetti M, Repetto E, Righi E, Boni S, Diverio M, et al. (2008) Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 61: 417-420.
34. Motaouakkil S, Charra B, Hachimi A, Nejmi H, Benslama A, et al. (2006) Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infection 53: 274-278.
35. Falagas ME, Rafailidis PI, Kasiakou SK, Hatzopoulou P, Michalopoulos A, (2006) Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections. Clin Microbiol Infect 12: 1227-1230.
36. Falagas ME, Rafailidis PI, Matthaiou DK, Virtzili S, Nikita D, et al. (2008) Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int J Antimicrob Agents 32: 450-454.
37. Ku K, Pogue JM, Moshos J, Bheemreddy S, Wang Y, et al. (2012) Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections. Am J Infect Control.
38. Deris ZZ, Yu HH, Davis K, Soon R, Jacob J, et al. (2012) Colistin and Doripenem Combination is Synergistic against Klebsiella pneumoniae at Multiple Inocula and Suppresses Colistin Resistance in an in vitro PK/PD Model. Antimicrob Agents Chemother.
39. Cai Y, Chai D, Wang R, Liang B, Bai N, (2012) Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 67: 1607-1615.
40. Centers for Disease Control and Prevention (2003) Treatment of tuberculosis. MMWR Recomm Rep 52: 1-77.
41. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, et al. (1998) Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 352: 1725-1730.
42. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853-860.
43. Vittinghoff E, Scheer S, O'Malley P, Colfax G, Holmberg SD, et al. (1999) Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis 179: 717-720.
44. Mouton JW, (1999) Combination therapy as a tool to prevent emergence of bacterial resistance. Infection 27 (Suppl 2): S24-28.
45. Mortensen BL, Skaar EP (2012) Host-microbe interactions that shape the pathogenesis of Acinetobacter baumannii infection. Cell Microbiol.
46. Roca I, Espinal P, Vila-Farres X, Vila J, (2012) The Acinetobacter baumannii Oxymoron: Commensal Hospital Dweller Turned Pan-Drug-Resistant Menace. Front Microbiol 3: 148.
47. Ho J, Tambyah PA, Paterson DL, (2010) Multiresistant Gram-negative infections: a global perspective. Curr Opin Infect Dis 23: 546-553.
48. Lee HW, Koh YM, Kim J, Lee JC, Lee YC, et al. (2008) Capacity of multidrug-resistant clinical isolates of Acinetobacter baumannii to form biofilm and adhere to epithelial cell surfaces. Clin Microbiol Infect 14: 49-54.
49. Lee JC, Koerten H, van den Broek P, Beekhuizen H, Wolterbeek R, et al. (2006) Adherence of Acinetobacter baumannii strains to human bronchial epithelial cells. Res Microbiol 157: 360-366.
50. Sopirala MM, Pope-Harman A, Nunley DR, Moffatt-Bruce S, Ross P, et al. (2008) Multidrug-resistant Acinetobacter baumannii pneumonia in lung transplant recipients. J Heart Lung Transplant 27: 804-807.
51. Duarte AG, Myers AC (2011) Cough Reflex in Lung Transplant Recipients. Lung.
52. Shyu S, Dew MA, Pilewski JM, DeVito Dabbs AJ, Zaldonis DB, et al. (2011) Five-year outcomes with alemtuzumab induction after lung transplantation. J Heart Lung Transplant 30: 743-754.
53. Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE, (2008) Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infection 56: 432-436.
54. Siempos, II, Vardakas KZ, Kyriakopoulos CE, Ntaidou TK, Falagas ME, (2010) Predictors of mortality in adult patients with ventilator-associated pneumonia: a meta-analysis. Shock 33: 590-601.
55. Pankey GA, Ashcraft DS, (2009) The detection of synergy between meropenem and polymyxin B against meropenem-resistant Acinetobacter baumannii using Etest and time-kill assay. Diagn Microbiol Infect Dis 63: 228-232.
56. Adams-Haduch JM, Paterson DL, Sidjabat HE, Pasculle AW, Potoski BA, et al. (2008) Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania. Antimicrob Agents Chemother 52: 3837-3843.